Relationship between serum VEGF level and radiosensitivity of patients with nonsmall cell lung cancer among asians: A meta-analysis

DNA and Cell Biology

Volumn 33, Issue 7, 2014, Pages 426-437

  Fu, Zhan Zhao ^a   Sun, Xiao Dong ^b   Li, Ping ^a   Zhang, Zhi ^b   Li, Guo Zhong ^b   Gu, Tao ^a   Shao, Sha Sha ^a  

^a FIRST HOSPITAL OF QINHUANGDAO   (China)

^b Tangshan Workers Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ARTICLE; ASIAN; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASE CONTROL STUDY; CINAHL; CLINICAL STUDY; COCHRANE LIBRARY; COHORT ANALYSIS; CORRELATIONAL STUDY; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MEDLINE; META ANALYSIS (TOPIC); OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RADIOSENSITIVITY; TREATMENT RESPONSE; VASCULOTROPIN BLOOD LEVEL;

ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; DATABASES AS TOPIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RADIATION TOLERANCE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84903315477     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2013.2249     Document Type: Article

References (76)

1. Arinaga, M., Noguchi, T., Takeno, S., Chujo, M., Miura, T., and Uchida, Y. (2003). Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 97, 457-464. (Pubitemid 36133813)
2. Ausborn, N.L., Le, Q.T., Bradley, J.D., Choy, H., Dicker, A.P., Saha, D., et al. (2012). Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 83, e453-e464.
3. Braicu, E.I., Fotopoulou, C., Chekerov, R., Richter, R., Blohmer, J., Kummel, S., et al. (2013). Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy. Cytokine 61, 755-758.
4. Brattstrom, D., Bergqvist, M., Hesselius, P., Larsson, A., Wagenius, G., and Brodin, O. (2004). Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer. Lung Cancer 43, 55-62. (Pubitemid 38096292)
5. Bray, F., Jemal, A., Grey, N., Ferlay, J., and Forman, D. (2012). Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol 13, 790-801.
6. Bremnes, R.M., Camps, C., and Sirera, R. (2006). Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51, 143-158. (Pubitemid 43144358)
7. Carmeliet, P., and Jain, R.K. (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298- 307.
8. Carrillo-de Santa Pau, E., Carrillo Arias, F., Caso Pelaez, E., Muguruza Trueba, I., Sanchez Hernandez, I., Munoz Molina, G.M., et al. (2010). Vascular endothelial growth factor (VEGF) serum levels are associated with survival in early stages of lung cancer patients. Cancer Invest 28, 393-398.
9. Choi, J.A., Hwang, J.U., Yoon, Y.H., and Koh, J.Y. (2013). Methallothionein-3 contributes to vascular endothelial growth factor induction in a mouse model of choroidal neovascularization. Metallomics 5, 1387-1396.
10. Choi, J.H., Kim, H.C., Lim, H.Y., Nam, D.K., Kim, H.S., Yi, J.W., et al. (2001). Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer 33, 171-179.
11. D'Andrea, L.D., Romanelli, A., Di Stasi, R., and Pedone, C. (2010). Bioinorganic aspects of angiogenesis. Dalton Trans 39, 7625-7636.
12. de Boer, R.H., Arrieta, O., Yang, C.H., Gottfried, M., Chan, V., Raats, J., et al. (2011). Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 29, 1067-1074.
13. Deng, H.B., Zhang, X.P., and Liu, Y. (2005). The study of p53, VEGF, MVD expressions and their correlations in non-small cell lung cancer. Cancer Res Prevent Treatm 32, 702-704, 741.
14. Di, Y., Fu, Z.Z., Gu, T., Gao, L.M., Qi, X.M., and Yang, Y.H. (2012). Clinical significance and expression level of VEGF/ PLT in serum and Opn before and after chemoradiotherapy in locally advanced non-small cell lung cancer. Chin J Coal Industry Med 15, 803-805.
15. Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., et al. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45, 228-247.
16. Farhat, F.S., Tfayli, A., Fakhruddin, N., Mahfouz, R., Otrock, Z.K., Alameddine, R.S., et al. (2012). Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Crit Rev Oncol Hematol 84, 149-160.
17. Faur, A.C., Lazar, E., and Cornianu, M. (2013). Vascular endothelial growth factor (VEGF) expression and microvascular density in salivary gland tumours. APMIS 1-9.
18. Ferrara, N. (2010). Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 21, 21-26.
19. Formica, V., Palmirotta, R., Del Monte, G., Savonarola, A., Ludovici, G., De Marchis, M.L., et al. (2011). Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis 26, 143-151.
20. Freeman, R., Girsh, J., Jou, A.F., Ho, J.A., Hug, T., Dernedde, J., et al. (2012). Optical aptasensors for the analysis of the vascular endothelial growth factor (VEGF). Anal Chem 84, 6192-6198.
21. Geng, L., Donnelly, E., McMahon, G., Lin, P.C., Sierra-Rivera, E., Oshinka, H., et al. (2001). Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61, 2413-2419. (Pubitemid 32685816)
22. Gu, T., Fu, Z.Z., Fu, B.H., Zhang, L.N., Zhang, S.H., and Cao, X.Y. (2011). Clinical significance of serum VEGF and TGFb1 by detecting their expression level before and after threedimensional conformal radiation therapy in elder patients with non-small cell lung cancer. Chin J Clin Oncol 38, 1565- 1567.
23. Gu, X., Cun, Y., Li, M., Qing, Y., Jin, F., Zhong, Z., et al. (2013). Human apurinic/apyrimidinic endonuclease siRNA inhibits the angiogenesis induced by X-ray irradiation in lung cancer cells. Int J Med Sci 10, 870-882
24. Guan, X., Yin, M., Wei, Q., Zhao, H., Liu, Z., Wang, L.E., et al. (2010). Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer 10, 431.
25. Guo, Z.W., Gong, Y.H., Li, Y., Xue, W.C., Yan, Y., and Tian, Q.H. (2002). Study on changes of vascular endothelial cell growth factor in serum with non small cell hung cancer patients before and after radiotherapy. Chin J Immunol 18, 807- 809.
26. He, W., Tang, B., Yang, D., Li, Y., Song, W., Cheang, T., et al. (2013). Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patients. World J Surg Oncol 11, 161.
27. Hicklin, D.J., and Ellis, L.M. (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23, 1011-1027. (Pubitemid 46202320)
28. Hirakawa, S., Brown, L.F., Kodama, S., Paavonen, K., Alitalo, K., and Detmar, M. (2007). VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 109, 1010-1017. (Pubitemid 46220646)
29. Huang, Z.J. (2010). Expression and significance of serum level of vascular endothelial growth factor in patients with nonsmall cell lung cancer undergoing radiotherapy. J Pract Med 26, 2503-2505.
30. Iwasaki, A., Kuwahara, M., Yoshinaga, Y., and Shirakusa, T. (2004). Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur J Cardiothorac Surg 25, 443-448. (Pubitemid 38340585)
31. Ji, X., Wang, Z., Sarkar, F.H., and Gupta, S.V. (2012). Deltatocotrienol augments cisplatin-induced suppression of nonsmall cell lung cancer cells via inhibition of the Notch-1 pathway. Anticancer Res 32, 2647-2655.
32. Jones, R.G., and Thompson, C.B. (2009). Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 23, 537-548.
33. Kawai, H., Minamiya, Y., Ito, M., Saito, H., and Ogawa, J. (2008). VEGF121 promotes lymphangiogenesis in the sentinel lymph nodes of non-small cell lung carcinoma patients. Lung Cancer 59, 41-47.
34. Kaya, A., Ciledag, A., Gulbay, B.E., Poyraz, B.M., Celik, G., Sen, E., et al. (2004). The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med 98, 632-636. (Pubitemid 38949927)
35. Kim, S.W., Kim, M.Y., Lee, Y.P., Ryu, Y.J., Lee, S.J., Lee, J.H., et al. (2013). Clinical features and prognostic factors in elderly koreans with advanced non-small-cell lung cancer in a tertiary referral hospital. Tuberc Respir Dis (Seoul) 75, 52-58.
36. Lim, E.H., Zhang, S.L., Li, J.L., Yap, W.S., Howe, T.C., Tan, B.P., et al. (2009). Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advancedstage non-small cell lung cancer (NSCLC). J Thorac Oncol 4, 12-21.
37. Linderholm, B., Tavelin, B., Grankvist, K., and Henriksson, R. (1999). Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer? Br J Cancer 81, 727-732.
38. Little, J., Higgins, J.P., Ioannidis, J.P., Moher, D., Gagnon, F., von Elm, E., et al. (2009). Strengthening the reporting of genetic association studies (STREGA) - an extension of the STROBE statement. Eur J Clin Invest 39, 247-266.
39. Loncaster, J.A., Cooper, R.A., Logue, J.P., Davidson, S.E., Hunter, R.D., and West, C.M. (2000). Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer 83, 620-625. (Pubitemid 30636303)
40. Ma, H., Bo, Y.J., Li, N., Yang, W.B., and Zhang, T.Y. (2010). Significance of combined determination of vascular endothelial growth factor, CA125 and carcinoembryanic antigen in peripheral blood of patients with non-small cell lung cancer. Chongqing Med J 39, 430-431, 433.
41. Maekawa, S., Iwasaki, A., Shirakusa, T., Enatsu, S., Kawakami, T., and Kuroki, M. (2007). Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma. Anticancer Res 27, 3735-3741. (Pubitemid 47598438)
42. Meng, L., Zhang, Y.D., and Wang, Y.B. (2010). Clinical significance of vascular endothelial growth factor C and CD44v6 expressions in hunam non-small cell lung cancer. J Shandong Univers (Health Science) 48, 83-86.
43. Molina, J.R., Yang, P., Cassivi, S.D., Schild, S.E., and Adjei, A.A. (2008). Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83, 584-594. (Pubitemid 351720831)
44. Naga Deepthi, C. (2011). Role of tumor suppressor protein p53 in apoptosis and cancer therapy. J Cancer Sci Ther S17, 001.
45. Naumnik, W., Nilklinska, W., Ossolinska, M., and Chyczewska, E. (2009). Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy. Folia Histochem Cytobiol 47, 703-709.
46. Niers, T.M., Richel, D.J., Meijers, J.C., and Schlingemann, R.O. (2011). Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. PLoS One 6, e19873.
47. Peters, J.L., Sutton, A.J., Jones, D.R., Abrams, K.R., and Rushton, L. (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA 295, 676-680. (Pubitemid 43209069)
48. Rades, D., Setter, C., Dunst, J., Dahl, O., Schild, S.E., and Noack, F. (2010). Prognostic impact of VEGF and VEGF receptor 1 (FLT1) expression in patients irradiated for stage II/III non-small cell lung cancer (NSCLC). Strahlenther Onkol 186, 307-314.
49. Saharinen, P., Eklund, L., Pulkki, K., Bono, P., and Alitalo, K. (2011). VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med 17, 347-362.
50. Salgia, R. (2011). Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer 117, 3889-3899.
51. Sano, D., Matsumoto, F., Valdecanas, D.R., Zhao, M., Molkentine, D.P., Takahashi, Y., et al. (2011). Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro. Clin Cancer Res 17, 1815-1827.
52. Senger, D.R. (2010). Vascular endothelial growth factor: much more than an angiogenesis factor. Mol Biol Cell 21, 377-379.
53. Shintani, Y., Okimura, A., Sato, K., Nakagiri, T., Kadota, Y., Inoue, M., et al. (2011). Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in nonsmall cell lung cancer. Ann Thorac Surg 92, 1794-1804.
54. Sina, K., Sonia, T., Xiujuan, L., Laura, G., and Lena, C.-W. (2011). Signal transduction by vascular endothelial growth factor receptors. Biochem J 437, 169-183.
55. Steffensen, K.D., Waldstrom, M., Brandslund, I., and Jakobsen, A. (2010). The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 117, 109-116.
56. Takahashi, S. (2011). Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull 34, 1785-1788.
57. Thangarajah, H., Yao, D., Chang, E.I., Shi, Y., Jazayeri, L., Vial, I.N., et al. (2009). The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci U S A 106, 13505-13510.
58. Tischler, V., Pfeifer, M., Hausladen, S., Schirmer, U., Bonde, A.-K., Kristiansen, G., et al. (2011). L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer. Mol Cancer 10, 127.
59. Toi, M., Matsumoto, T., and Bando, H. (2001). Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol 2, 667-673. (Pubitemid 33085812)
60. Topkan, E., Parlak, C., Topuk, S., Guler, O.C., and Selek, U. (2013). Outcomes of aggressive concurrent radiochemotherapy in highly selected septuagenarians with stage IIIB non-small cell lung carcinoma: retrospective analysis of 89 patients. Lung Cancer 81, 226-230.
61. Tsutsui, S., Matsuyama, A., Yamamoto, M., Takeuchi, H., Oshiro, Y., Ishida, T., et al. (2010). The Akt expression correlates with the VEGF-A and -C expression as well as the microvessel and lymphatic vessel density in breast cancer. Oncol Rep 23, 621-630.
62. Veeravagu, A., Hsu, A.R., Cai, W., Hou, L.C., Tse, V.C., and Chen, X. (2007). Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as antiangiogenic agents in cancer therapy. Recent Pat Anticancer Drug Discov 2, 59-71. (Pubitemid 46723152)
63. Wang, H.B., Lin, Y.C., Lin, W.Z., Zeng, D., Lin, W., and Hong, C.Q. (2008). Clinical significance of serum vascular endothelial growth factor in advanced malignant tumors. Chin Clin Oncol 13, 126-128.
64. Wang, R.H., Xie, J.G., Chen, H., Ren, T.T., and Zhang, Y.C. (2013). Expression of angiopoietin-2 and vascular endothelial growth factor in human colon cancer. Nan Fang Yi Ke Da Xue Xue Bao 33, 1236-1239.
65. Wang, Y.P., Wang, M.Z., Luo, Y.R., Wei, Z.X., and Xuan, Y.P. (2012). Clinical study of vaecular endothelial frowth factor-C and cytokeratin 19 in stage I non-small cell lung cancer patients. Chin J Clin Thorac Cardiovasc Surg 19, 385-389.
66. Weis, S.M., and Cheresh, D.A. (2011). Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17, 1359-1370.
67. Yang, S.Y., Zhong, Z.P., Hu, L.J., Wang, J.J., Cai, P., and Shi, D.P. (2011). A clinical analysis of the whole body therm aerotherapy for patients with nin-small cell lung cancer after operation. Chin J Clin Oncol Rehabilit 18, 66-68.
68. Yilmaz, A., Ernam, D., Unsal, E., Demirag, F., Atikcan, S., and Tastepe, I. (2007). Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer. Arch Med Res 38, 764-768. (Pubitemid 47368722)
69. Yin, M., Liao, Z., Yuan, X., Guan, X., O'Reilly, M.S., Welsh, J., et al. (2012). Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. Cancer Sci 103, 945-950.
70. Zhang, H.J., Guo, W.D., Niu, D.S., Di, J.J., Li, H.L., Geng, C.L., et al. (2010). Observation on efficacy of radiotherapy combined with hyperthermia in treatment of non-small cell lung cancer and significance of change of VEGF, sIL-2R and IL-6. Chin J Clin Oncol Rehabilit 17, 299-304.
71. Zhang, S., Hu, L.K., Xu, M., Fu, L., and Zhu, X.L. (2008). Significance of serum vascular endothelial growth factor in non-small cell lung cancer. J Shandong Uni (Health Sciences) 46, 1177-1180.
72. Zhang, W.C., Shyh-Chang, N., Yang, H., Rai, A., Umashankar, S., Ma, S., et al. (2012a). Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 148, 259-272.
73. Zhang, Y., Yu, L.K., and Xia, N. (2012b). Evaluation of serum and pleural levels of endostatin and vascular epithelial growth factor in lung cancer patients with pleural effusion. Asian Pac J Trop Med 5, 239-242.
74. Zhao, X.F., Liu, X.Q., Guo, W.F., and Li, X.B. (2010). Expression of carbonic anhydrase IX in NSCLC and its Relationship with VEGF and Ki67 expression. Chin J Lung Cancer 13, 861-866.
75. Zhou, W.B., Bai, M., and Jin, Y. (2009). Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions. Int J Tuberc Lung Dis 13, 381-386.
76. Zintzaras, E., and Ioannidis, J.P. (2005). HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics 21, 3672-3673. (Pubitemid 41264106)